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In the present review article, we present an overview of beta-adrenoceptor (β-AR) sub-
type expression at the mRNA and receptor protein levels in the human detrusor, the 
in vitro and in vivo bladder function of the β3-AR, the in vivo effect of β3-AR agonists 
on detrusor overactivity in animal models, and the available results of clinical trials 
of β3-AR agonists for treating overactive bladder (OAB). There is a predominant ex-
pression of β3-AR mRNA in human bladder, constituting 97% of total β-AR mRNA. Also, 
functionally, the relaxant response of human detrusor to catecholamines is mainly 
mediated through the β3-ARs. Moreover, the presence of β1-, β2-, and β3-AR mRNAs 
in the urothelium and suburothelial layer of human bladder has been identified. 
Stimulation of urothelial β-ARs results in the release of nitric oxide and an unknown 
substance inhibiting detrusor contractions from the urothelium. Intravenous applica-
tion of CL316,243, a selective β3-AR agonist, in rats selectively inhibits mechano-sensi-
tive Aδ-fiber activity of the primary bladder afferents. A number of selective β3-AR ago-
nists are currently being evaluated in clinical trials for OAB with promising prelimi-
nary results. In conclusion, the β3-AR agonists are the most notable alternative class 
of agents to antimuscarinics in the pharmacological treatment of OAB. The β3-AR ago-
nists act to facilitate bladder storage function probably through at least two mecha-
nisms: first, direct inhibition of the detrusor, and second, inhibition of bladder afferent 
neurotransduction.
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INTRODUCTION
Activation of beta-adrenoceptors (β-ARs) is involved in the 
bladder relaxation induced by sympathetic nerve activa-
tion during the storage phase. β-ARs were originally classi-
fied into two different subtypes, β1- and β2-ARs, on the ba-
sis of the different physiological effects of their ligands [1]. 
The classification of β-AR was modified following the dis-
covery of a third β-AR primarily in rat adipose tissue in the 
1980s [2]. Human β3-AR was cloned in 1989 and was ini-
tially identified in adipose tissue [3]. More recent reports 
indicate that β3-ARs are also expressed in human heart, 
gall bladder, gastrointestinal tract, prostate and urinary 
bladder detrusor, and brain [2]. In the late 1970s it was re-
ported that isoproterenol-induced relaxation of human de-
trusor muscle is not blocked by practolol (a selective β1-AR 
antagonist) or butoxamine (a selective β2-AR antagonist), 
thus predicting the existence of a third β-AR subtype [4,5]. 
Later studies after the discovery of a new subtype (β3-AR) 
in various species to identify the functional involvement of 
β-AR subtypes in bladder relaxation demonstrated species 
differences. It has been suggested that the relaxation in-
duced by β-AR agonists in detrusor muscle may be medi-
ated mainly via β2-AR in rabbits [6-8], via both β2- and 
β3-AR in rats [6-10], via β2-AR and possibly β3-AR in pigs 
[11], but predominantly via β3-AR in dogs [8,10]. Which 
subtypes, then, are responsible for the relaxation of human 
detrusor?Korean J Urol 2010;51:811-818
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FIG. 1. Primary structure of the human 
beta3-adrenoceptor. Taken with per-
mission from Ursino et al (2009) [2]. 
PKA: cAMP-dependent protein kinase,
β-ARK: beta-adrenergic receptor ki-
nase.
STRUCTURE OF HUMAN β3-ARs
The gene encoding the β3-AR has been cloned in several 
species: human [3], rat, mouse, bovine, monkey, and dog 
[12]. Human β3-ARs share 51% and 46% identity with the 
β1- and β2-AR amino acid sequences, respectively [3]. In 
humans, the gene is localized on chromosome 8. The rat and 
human β3-AR are 79% identical; the highest homology is 
in the transmembrane domains (94%), whereas the lowest 
homology is observed in the C-terminal tail and the third 
intracellular loop [2]. The β3-AR, together with β1- and 
β2-ARs, belongs to the G-protein coupled receptor family 
characterized by seven transmembrane domains of 22 to 
28 amino acids, with three intracellular and three ex-
tracellular loops (Fig. 1) [2,3,12]. The N-terminal region of 
these receptors is extracellular and glycosylated, whereas 
the C-terminus is intracellular. The transmembrane do-
mains, TM3, TM4, TM5, and TM6, are essential for ligand 
binding, whereas TM2 (which contains Asp83) and TM7 
(which contains Tyr336) are involved in Gs activation [3]. 
The disulphide bond between Cys110 in the second and 
Cys189 in the third extracellular loops is essential for li-
gand binding and activity of the receptor. The Cys361 resi-
due in the fourth intracellular domain is palmitoylated. 
Palmitoylation has been shown to mediate adenylate cy-
clase stimulation by agonist-bound receptor, possibly by 
promoting the insertion of several adjacent residues in the 
membrane and thus forming an additional intracellular 
loop resulting in an active conformation for G-protein cou-
pling [2,13].
β-AR SUBTYPE EXPRESSION AT THE mRNA 
LEVEL IN THE HUMAN DETRUSOR
The expression of β1-, β2-, and β3-AR mRNA in the human 
bladder has been reported [14-17]. The presence of β3-AR 
mRNA in the human detrusor has also been confirmed in 
in situ hybridization studies [16]. It has also been demon-
strated by use of a real-time quantitative polymerase chain 
reaction (PCR) that of all the β-AR mRNA in human blad-
der, 97% is represented by the β3-AR subtype and only 1.5% 
and 1.4% by the β1- and β2-AR subtypes, respectively [17]. 
Although a predominant expression of β3-AR mRNA was 
found in human detrusor tissue, evidence that the predom-
inant subtype is the β3-AR cannot be drawn from this study 
in which only the receptor mRNA concentrations were de-
termined without simultaneous determination of the re-
ceptor protein. Thus, whether the β3-AR is the most abun-
dant subtype in human detrusor muscle remains to be elu-
cidated [18].
β-AR SUBTYPE EXPRESSION AT THE RECEPTOR 
PROTEIN LEVEL
The identification of β-ARs at the protein level is typically 
based on binding studies with various radioligands. 
Limited attempts have been made to identify the β-AR sub-
types in the bladder by radioligand binding, demonstrating 
that sites in the rabbit and human bladder belong largely 
to the β2-AR subtype. However, the radioligands used in 
these studies have much lower affinity for β3- than for β1- 
and β2-ARs. Because of such problems, the currently avail-
able radioligand-binding techniques are probably in-
adequate to detect the presence of β3-ARs at the protein lev-
el because of the lack of selective ligands for β3-ARs [19,20].
IN VITRO FUNCTION IN RELAXING HUMAN 
DETRUSOR
In the human detrusor, Igawa et al originally reported that 
bupranolol (a nonselective β-AR antagonist) at a low con-
centration (10
-8 M) did not inhibit isoproterenol-induced 
relaxation, but at higher concentrations (10
-7-10
-5 M), the 
drug caused a rightward shift of the concentration-relaxation 
curve for isoproterenol in a dose-dependent manner [21]. 
This suggests that the relaxation-induced adrenergic sti-
mulation in the human detrusor is mediated mainly by β3- 
AR, rather than β1- or β2-AR, because bupranolol is known Korean J Urol 2010;51:811-818
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FIG. 2. Inhibition of isoprenaline-induced relaxation of human bladder detrusor by the β1-AR antagonist CGP 20,712, the β2-AR 
antagonist ICI 118,551, and the β3-AR antagonist SR 58,894. Taken with permission from Igawa et al (1999) [14].
to have antagonistic action only on β1- and β2-ARs at low 
concentrations (nM), whereas at higher concentrations 
(μM) it also affects the β3-AR. In addition to the findings 
with bupranolol, neither dobutamine (a β1-AR agonist) nor 
procaterol (a β2-AR agonist) produced significant relaxa-
tion in the human detrusor [14,21]. On the other hand, the 
selective  β3-AR agonists, BLR37,344, CL316,243, and 
CGP12,177A, all produced concentration-dependent re-
laxation [14,16]. Furthermore, isoproterenol-induced re-
laxation was inhibited by the selective β3-AR antagonists 
(SR58,894A), but not by the selective β1-AR antagonist 
(CGP20,712A), nor by the selective β2-AR antagonist 
(ICI118,551) (Fig. 2) [14]. In agreement with the predom-
inant expression of β3-AR mRNA in the human bladder 
(see above), these findings indicate that the relaxation in-
duced by β-adrenergic stimulation of the human detrusor 
is mediated mainly through β3-AR activation. Thus, this 
subtype is likely to be the most important for bladder relax-
ation in vitro.
　Few studies have focused on possible changes in β-AR re-
sponsiveness in human detrusor in pathological conditions 
such as neurogenic bladder. A comparative study of neuro-
genic (low compliance or overactive) bladder preparations 
with controls was reported on the relaxant responses to iso-
proterenol (non-subtype-selective β-AR agonist) and three 
kinds of selective β3-AR agonists, BRL37,344, CL 316,243, 
and CGP 12,177. Agonist potency was similar in all three 
groups for each agonist, and maximum effects were also 
similar across the groups for the agonists, except for an in-
creased effect of CGP 12,177 in low-compliance bladders 
[22]. These findings suggest that β3-AR-mediated relaxa-
tion can be preserved even in bladder tissues taken from 
patients with neurogenic low-compliant or overactive blad-
der (OAB). Nomiya and Yamaguchi compared bladder 
preparations taken from male patients with and without 
bladder outlet obstruction and found that potency and 
maximum effects of isoproterenol and L755,507 (the β3-AR 
agonist) were similar in both groups, although there were 
statistically significant differences in the abundance of β1-, 
β2-, or β3-adrenoceptor mRNA between the groups [17]. Korean J Urol 2010;51:811-818
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Taken together, even though the available human data 
were limited, it seems likely that the β-AR responsiveness 
can be largely preserved even in the human detrusor in 
states of bladder dysfunction.
IN VIVO FUNCTION
The in vivo effects of β-AR agonists on bladder function 
have been studied in animal models. In urethane-anaes-
thetized rats, isoproterenol, the β2-agonist procaterol, and 
the β3-agonist CL316,243 dose-dependently decreased in-
travesical pressure in an isovolumetric condition. CL316, 
243 had only a slight influence on blood pressure and heart 
rate, whereas isoproterenol and procaterol significantly af-
fected cardiovascular function at the same dose range as 
that required to reduce bladder pressure. In cystometry ex-
periments, CL316,243 (10 μg/kg i.v.) significantly pro-
longed the micturition interval and increased bladder ca-
pacity, but did not change the residual volume. On the other 
hand, procaterol (100 μg/kg i.v.) prolonged the micturition 
interval and increased bladder capacity but also increased 
residual volume [23]. In another study, both procaterol and 
CL316,243 reduced intravesical pressure in urethane- 
anaesthetized rats; the effect of procaterol was inhibited 
by ICI118,551 and the CL316,243 effect by the β3-AR an-
tagonist L748,337, whereas neither antagonist affected 
the response to the other agonist [10]. In conscious, unre-
strained rats, intravenous administration of procaterol did 
not affect voiding pressure relative to vehicle and had little 
effect on bladder capacity, whereas CL316,243 had no ef-
fect on bladder capacity but reduced voiding pressure [24]. 
These data suggest that both β2- and β3-adrenoceptors 
contribute to bladder relaxation in rats in vivo, which is 
consistent with the available in vitro data (see above).
IN VIVO EFFECT OF β3-AR AGONISTS ON 
DETRUSOR OVERACTIVITY IN RAT MODELS
It was shown that CL316,243 (β3-AR agonist) can improve 
detrusor overactivity at the doses studied without affecting 
the cardiovascular system or voiding function in rat experi-
mental models associated with cerebral infarction [24], 
bladder outlet obstruction and intravesical instillation of 
acetic acid [25], and intravesical instillation of prosta-
glandin (PG) E2 [26], thus predicting the usefulness of 
β3-AR agonists in the treatment of OAB. The effect of 
CL316,243 was also investigated in a model of detrusor 
overactivity in spontaneously hypertensive rats (SHRs) 
[27]. CL316,243 inhibited bladder rhythmic contractions 
in SHRs, decreasing both frequency and amplitude of 
contraction. CL316,243 failed to reduce visceromotor re-
flex (VMR) or pressor responses to urinary bladder dis-
tension in either SHRs or normotensive control rats, which 
suggests that the β3-AR agonist inhibits bladder functions 
by acting directly on the detrusor. Together, these results 
suggest that the activation of β3-ARs increases bladder ca-
pacity without influencing bladder contraction or residual 
urine volume during the voiding phase in commonly used 
animal models of detrusor overactivity. This character dis-
tinguishes β3-AR agonists from antimuscarinic agents, 
which produce urinary retention by decreasing the in-
tensity of detrusor contraction. With regard to why β3-AR 
agonists do not affect voiding function, the following mech-
anism may be considered. The activation of β3-AR de-
creases bladder smooth muscle tone through an increase 
in adenylate cyclase activity during the filling phase. 
During the voiding phase, acetylcholine released from par-
asympathetic nerves activates postjunctional muscarinic 
M2 receptors and inhibits the increased adenylate cyclase 
activity mediated by β3-ARs. At the same time, acetylcho-
line also stimulates muscarinic M3 receptors and activates 
the phosphatidylinositol-Ca
2+ recruitment system, which 
preserves voiding bladder contractions independently 
[18,24,25,28-30]. Thus, under the administration of β3-AR 
agonists, at the beginning of the voiding phase, the relaxa-
tion of bladder smooth muscle may be canceled by muscar-
inic M2-receptor activation, but muscarinic M3-receptor- 
mediated bladder contraction can remain intact, sugges-
ting in turn little risk of β3-AR agonists for causing the urinary 
retention noted with antimuscarinic agents. However, re-
cent studies at least in the rat bladder have questioned 
cAMP-dependent routes as the exclusive mechanisms for 
triggering the β-AR-mediated relaxation [18,31,32]. There-
fore, the in vivo effect of β3-AR agonists to increase bladder 
capacity without influencing bladder contraction cannot 
be simply explained [18]. Nevertheless, if this character-
istic of β3-AR agonists is the case also in humans, the β3-AR 
agonists may have an advantage over antimuscarinics, es-
pecially in OAB patients with associated bladder outlet 
obstruction.
β-ARs IN THE UROTHELIUM, SUBUROTHELIUM, 
AND NERVES
Otsuka et al confirmed the presence of β1-, β2-, and β3-AR 
in human urinary bladder urothelium by RT-PCR and im-
munohistochemistry [33]. It has been shown that activa-
tion of β-AR by isoproterenol in rat urothelial cells can re-
lease nitric oxide (NO) through an increase in intracellular 
Ca
2+ by cAMP accumulation [34]. Activation of urothelial 
β-AR releases not only NO but also a urothelial-derived fac-
tor that inhibits contractions induced by carbachol in the 
pig detrusor [35]. The β-AR involved in the release of ur-
othelial-derived inhibitory factor (UDIF) was recently de-
termined to be a β3-subtype [36]. A similar UDIF released 
by β-AR activation in the human bladder urothelium is re-
ported to inhibit the β-AR agonist-induced relaxation of the 
human detrusor smooth muscle [33].
　The presence of all three β-AR subtypes has been demon-
strated also in suburothelial interstitial cells of the human 
bladder by immunohistochemistry [37]. More recently, 
Limberg et al reported that in human female bladder, im-
munostaining for β1-, β2-, and β3-ARs was each more prom-
inent in the urothelium than in the detrusor, with all re-Korean J Urol 2010;51:811-818
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FIG. 3. Relaxing effect of isoproterenol, YM178, and CGP-12177A in rat (A) and human (B) bladder strips precontracted with 
carbachol. Taken with permission from Takasu et al (2007) [30].
ceptors expressed in the same cell types, indicating co-ex-
pression of all three receptors throughout the urothelium 
in addition to the detrusor [38]. The authors demonstrated 
staining of all the three β-AR subtypes also in suburothelial 
myofibroblast-like cells, intramural ganglion cells, and in 
Schwann cells of intramural nerves, suggesting that acti-
vation of the myocyte receptor may be influenced by action 
on non-myocyte structures including the intramural gan-
glion cells and myofibroblasts. Aizawa et al reported, by use 
of a single-unit afferent activity monitoring procedure of 
the mechanosensitive primary bladder afferent nerves in 
the rat, that systemic activation of β3-ARs by intravenous 
administration of CL316,243 inhibits the mechanosensi-
tive Aδ afferent fiber activity and PGE2-induced C-fiber 
hyperactivity [39]. This may imply that β3-AR agonists act 
as therapeutic agents for facilitating bladder storage func-
tion through at least two mechanisms: first, direct in-
hibition of the detrusor, and second, inhibition of bladder 
afferent neurotransduction.
DIFFERENCES IN β3-AR BETWEEN RODENTS 
AND HUMANS
BRL37344, CL316,243, and CGP-12,177A are representa-
tive β3-AR agonists that were optimized by using rodent 
β-ARs [19,40,41]. These compounds have lower potency for 
human β3-ARs than for rodent receptors, and they act as 
only partial agonists in humans [14,18-20,22,42]. Subse-
quent recognition of important pharmacological differ-
ences between rodent and human β3-ARs has led to the de-
velopment of novel β3-AR agonists that are potent and 
highly selective toward human β3-ARs [19,30,42,43]. 
NEW GENERATION OF β3-AR AGONISTS
YM178, which was synthesized by Astellas Pharma Inc. 
(Ibaraki, Japan), showed highly selective agonist activity 
for human β3-AR over β1- or β2-AR. The agonistic potency 
of YM178 for human β3-ARs was 20 and 200 times that of 
BRL37344 and CL316,243, respectively [30]. In addition, 
the intrinsic activity of YM178 for human β3-ARs was high-
er than that of BRL37344 and CL316,243 [30]. In rat and 
human bladder strips precontracted with carbachol, YM 
178 and isoproterenol concentration-dependently induced 
relaxation (Fig. 3), indicating full agonistic action for 
YM178 in both rat and human detrusor relaxation. In an-
aesthetized rats, YM 178, given intravenously at a dose of 
3 mg/kg, decreased the frequency of rhythmic bladder con-
tractions induced by intravesical filling with saline with-
out suppressing its amplitude [30]. 
　A recent study investigated the effects of another novel 
selective β3-AR agonist GW427353 (solabegron) on bladder 
function in dogs by use of in vitro and in vivo techniques. 
The relaxation evoked by this compound was attenuated 
by the nonselective β-AR antagonist bupranolol and SR 
59230A (a selective β3-AR antagonist), but not by atenolol 
(a selective β1-AR antagonist) or ICI118,551 (a selective β2- 
AR antagonist). GW427,353 also increased the volume re-
quired to evoke micturition in anesthetized dogs following 
acetic acid-induced bladder overactivity without affecting 
voiding efficiency [44]. The effect of GW427,353 on human 
bladder strips was also reported [45]; the compound pro-
duced significant relaxation at concentrations of ＞10
-7 M; 
isoproterenol produced a significant effect from 10
-6 M, but 
otherwise both agonists had similar effects. GW427,353 at 
10
-6 M significantly reduced spontaneous activity within 10 
min of incubation and at higher concentrations (＞5x10
-6 
M) inhibited detrusor contractions evoked by electrical 
field stimulation [45].
CLINICAL TRIALS OF β3-AR AGONISTS FOR 
TREATING OAB
Together, these results have encouraged the clinical devel-
opment of β3-AR agonists for the treatment of OAB. 
Patients with OAB are usually treated with muscarinic re-Korean J Urol 2010;51:811-818
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ceptor antagonists, but the side effects of those antagonists 
as well as their poor efficacy in some patients have stimu-
lated interest in the development of new β3-AR subtype- 
selective agonists. In this context, β3-ARs are now consid-
ered an attractive target in the management of this clinical 
condition. The β3-AR agonists solabegron and YM178 are 
currently in Phase II and Phase III clinical trials, re-
spectively, for the treatment of OAB [46].
　Chapple et al reported the results of a phase IIA trial of 
YM178 in patients with OAB, which was clinical proof of 
a concept (Blossom) study conducted in several European 
countries [47]. The study enrolled 314 patients with OAB 
symptoms, and 262 patients were randomly assigned to 4 
groups: placebo, YM178 100 mg bid, YM178 150 mg bid, and 
tolterodine 4 mg qd for a 4-week treatment period. The pri-
mary endpoint was to evaluate efficacy, and the primary 
efficacy variable was the change in the mean number of 
micturitions per 24 hours as recorded on a frequency/vol-
ume chart. Both the YM178 100 mg and 150 mg treatment 
groups showed significant improvements in the mean 
number of micturitions per 24 hours compared with the 
placebo group (−2.19 and −2.21 vs. −1.18, respectively). 
The change in mean volume voided was dose-dependently 
increased in the YM178 treatment groups, and the YM178 
150 mg treatment group showed a significant increase in 
this variable compared with the placebo group. Urgency ep-
isodes per 24 hours significantly decreased in both the 
YM178 100 mg and 150 mg treatment groups compared 
with the placebo group. No severe adverse events were re-
ported and treatment was generally well tolerated. A 
small, mean increase in pulse rate with YM178 150 mg (5 
beats per minute) was demonstrated, but this was not asso-
ciated with a clinically significant increase in adverse 
events such as tachycardia and palpitations. All together, 
this phase IIA trial of YM178 was the first proof of concept 
study for β3-AR agonists improving OAB symptoms.
　Following this promising result, a phase IIB trial of 
YM178 for OAB was carried out in Europe [48]. This trial 
was a dose-ranging study of once-daily mirabegron (an ex-
tended release formula of YM178) in OAB patients. A total 
of 928 patients were randomly assigned in 5 study arms 
(placebo, mirabegron [YM178] 25 mg, 100 mg, 150 mg, and 
200 mg qd, for a 12-week treatment period), and the pri-
mary endpoint was to evaluate the dose-response relation-
ship on efficacy. The mean number of micturitions per 24 
hours decreased dose-dependently, and the decreases were 
statistically significant with mirabegron 50 mg and over 
compared with placebo. The mean volume voided per mic-
turition also increased dose-dependently, and the in-
creases were significantly greater with mirabegron 50 mg 
and over compared with placebo. In total, 45.2% of patients 
experienced adverse events, and the incidence of adverse 
events was similar among all treatment groups (placebo 
43.2% vs. mirabegron 43.8-47.9%). The overall discontinu-
ation rate owing to adverse events was 3.2% (placebo 3.0% 
vs. mirabegron 2.4-5.3%). The most commonly reported 
class of adverse events considered to be treatment-related 
by the investigators was gastrointestinal disorders, in-
cluding constipation, dry mouth, dyspepsia, and nausea. 
There was no patient-reported acute retention. No sig-
nificant difference in ECG parameters between the groups 
was demonstrated. However, a small but significant in-
crease in mean pulse rate was associated with mirabegron 
100 mg and 200 mg (1.6 and 4.1 beats per minute, re-
spectively), although this was not in accordance with an in-
crease in cardiovascular adverse events. 
CONCLUSIONS
Highly potent selective agonists for human β3-ARs have 
been developed. Although the available information on 
clinical trials of this class of agents for treating OAB is lim-
ited, some of these agents are expected to be the most nota-
ble alternative class to antimuscarinics in the pharmaco-
logical treatment of OAB. The β3-AR agonists can be used 
to treat OAB, especially in patients with benign prostatic 
hyperplasia, without increasing postvoid residuals, which 
is an advantage over antimuscarinics. These agents may 
be therapeutic candidates also for bladder hypersensiti-
vity related to facilitation of C-fiber activity of the primary 
bladder afferents.
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